Charalambos Andreadis, MD, Oncology, San Francisco, CA, UCSF Medical Center

CharalambosIAndreadisMD

Oncology San Francisco, CA

Hematologic Oncology

UCSF BMT

Dr. Andreadis is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Andreadis' full profile

Already have an account?

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Hematology/Oncology, 2001 - 2005
  • New York Presbyterian Hospital
    New York Presbyterian HospitalResidency, Internal Medicine, 1998 - 2001
  • Columbia University College of Physicians & Surgeons
    Columbia University College of Physicians & SurgeonsClass of 1998

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2008 - 2021
  • NY State Medical License
    NY State Medical License 2004 - Present
  • PA State Medical License
    PA State Medical License 2001 - 2008
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
    Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...
    Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
    Charalambos Andreadis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Ofatumumab, Etoposide and Cytarabine Intensive Mobilization Regimen in Patients with High-Risk Relapsed/Refractory Diffuse Large B-cell Lymphoma Undergoing Autologous Stem Cell Transplantation
    Ofatumumab, Etoposide and Cytarabine Intensive Mobilization Regimen in Patients with High-Risk Relapsed/Refractory Diffuse Large B-cell Lymphoma Undergoing Autologous Stem Cell TransplantationNovember 10th, 2020
  • AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
    AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences ConferenceApril 1st, 2019
  • Novel Oral TKI in Chronic Leukemia Requires Genetic Testing, Adherence to Therapy
    Novel Oral TKI in Chronic Leukemia Requires Genetic Testing, Adherence to TherapyMay 31st, 2015
  • Join now to see all

Other Languages

  • Greek

Hospital Affiliations